N
Nucleus RadioPharma
Transforming lives with radiopharmaceuticals by leveraging world class clinical, development, manufacturing, and supply chain expertise
About Nucleus RadioPharma
Nucleus RadioPharma is a startup that operates as a Contract Development and Manufacturing Organization (CDMO). In simpler terms, it provides services to help other companies develop and manufacture their products, specifically in the field of targeted radiotherapies. These are treatments that use radioactive substances to specifically target and kill cancer cells.
Read full description
The company's clients are innovators in the healthcare sector who are developing promising drug candidates. Nucleus RadioPharma helps them turn these candidates into commercially successful medicines by providing services like product development, regulatory expertise, manufacturing infrastructure, and supply chain networks.
The company's business model is based on providing end-to-end support to its clients. This means that it helps clients at every stage of their product lifecycle, from formulation and analytical development to regulatory documentation, drug product manufacturing, and distribution to patients.
Nucleus RadioPharma is also strategically located near prominent medical centers and key distribution hubs. This allows the company to access large clinical trial networks and deliver products to patients quickly.
The company's services are flexible and designed to expand as demand increases. This means that clients can come to Nucleus RadioPharma at any point in their product lifecycle and receive the services they need to advance their program.
In terms of revenue, Nucleus RadioPharma makes money by charging its clients for the services it provides.
At a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Rochester, United States
- Employees
- 57
- Open positions
- 6
- Dealroom signal
- 89.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Health Diagnostics, Spinout, Biotech and Pharma, Radiopharmaceuticals, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Apr 2026 | $50M | — | OrbiMed | ↗ |
| SERIES AOther financing | Jun 2024 | — | — | Mayo Clinic · AstraZeneca · Eclipse Ventures · Fox Chase Cancer Center | ↗ |
Growth signals
Latest recorded traffic for Nucleus RadioPharma is 5.5K monthly website visits, up 61.8% over the last three months. Nucleus RadioPharma's team grew 21.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Mayo Clinic
Eclipse Ventures
Series A6 investors entered at this stage
Mercy Health
GE Healthcare- GMGranger Management
Fox Chase Cancer Center
Echo Global Logistics
AstraZeneca
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nucleus RadioPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nucleus RadioPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.